FOXO1 overexpression and loss of pSerine256-FOXO1 expression predicts clinical outcome in esophageal adenocarcinomas
Standard
FOXO1 overexpression and loss of pSerine256-FOXO1 expression predicts clinical outcome in esophageal adenocarcinomas. / Grupp, Katharina; Uzunoglu, Faik Güntac; Melling, Nathaniel; Hofmann, Bianca; El Gammal, Alexander Tarek; Grotelüschen, Rainer; Heumann, Asmus; Bellon, Eugen; Reeh, Matthias; Wolters-Eisfeld, Gerrit; Ghabdan, Tarik; Nentwich, Michael; Bachmann, Kai; Bockhorn, Maximillian; Bogoevski, Dean; Izbicki, Jakob Robert; Kutup, Asad.
in: SCI REP-UK, Jahrgang 8, Nr. 1, 26.11.2018, S. 17370.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - FOXO1 overexpression and loss of pSerine256-FOXO1 expression predicts clinical outcome in esophageal adenocarcinomas
AU - Grupp, Katharina
AU - Uzunoglu, Faik Güntac
AU - Melling, Nathaniel
AU - Hofmann, Bianca
AU - El Gammal, Alexander Tarek
AU - Grotelüschen, Rainer
AU - Heumann, Asmus
AU - Bellon, Eugen
AU - Reeh, Matthias
AU - Wolters-Eisfeld, Gerrit
AU - Ghabdan, Tarik
AU - Nentwich, Michael
AU - Bachmann, Kai
AU - Bockhorn, Maximillian
AU - Bogoevski, Dean
AU - Izbicki, Jakob Robert
AU - Kutup, Asad
PY - 2018/11/26
Y1 - 2018/11/26
N2 - The function of Forkhead box O 1 (FOXO1) and pSerine256-FOXO1 immunostaining in esophageal cancer is unclear. To clarify the prognostic role of nuclear FOXO1 and cytoplasmic pSerine256-FOXO1 immunostaining, a tissue microarray containing more than 600 esophageal cancers was analyzed. In non-neoplastic esophageal mucosae, FOXO1 expression was detectable in low and pSerine256-FOXO1 expression in high intensities. Increased FOXO1 and decreased pSerine256-FOXO1 expression were linked to advanced tumor stage and high UICC stage in esophageal adenocarcinomas (EACs) (tumor stage: p = 0.0209 and p < 0.0001; UICC stage: p = 0.0201 and p < 0.0001) and squamous cell carcinomas (ESCCs) (tumor stage: p = 0.0003 and p = 0.0016; UICC stage: p = 0.0026 and p = 0.0326). Additionally, overexpression of FOXO1 and loss of pSerine256-FOXO1 expression predicted shortened survival of patients with EACs (p = 0.0003 and p = 0.0133) but were unrelated to outcome in patients with ESCCs (p = 0.7785 and p = 0.8426). In summary, our study shows that overexpression of nuclear FOXO1 and loss of cytoplasmic pSerine256-FOXO1 expression are associated with poor prognosis in patients with EACs. Thus, evaluation of FOXO1 and pSerine256-FOXO1 protein expression - either alone or in combination with other markers - might be useful for prediction of clinical outcome in patients with EAC.
AB - The function of Forkhead box O 1 (FOXO1) and pSerine256-FOXO1 immunostaining in esophageal cancer is unclear. To clarify the prognostic role of nuclear FOXO1 and cytoplasmic pSerine256-FOXO1 immunostaining, a tissue microarray containing more than 600 esophageal cancers was analyzed. In non-neoplastic esophageal mucosae, FOXO1 expression was detectable in low and pSerine256-FOXO1 expression in high intensities. Increased FOXO1 and decreased pSerine256-FOXO1 expression were linked to advanced tumor stage and high UICC stage in esophageal adenocarcinomas (EACs) (tumor stage: p = 0.0209 and p < 0.0001; UICC stage: p = 0.0201 and p < 0.0001) and squamous cell carcinomas (ESCCs) (tumor stage: p = 0.0003 and p = 0.0016; UICC stage: p = 0.0026 and p = 0.0326). Additionally, overexpression of FOXO1 and loss of pSerine256-FOXO1 expression predicted shortened survival of patients with EACs (p = 0.0003 and p = 0.0133) but were unrelated to outcome in patients with ESCCs (p = 0.7785 and p = 0.8426). In summary, our study shows that overexpression of nuclear FOXO1 and loss of cytoplasmic pSerine256-FOXO1 expression are associated with poor prognosis in patients with EACs. Thus, evaluation of FOXO1 and pSerine256-FOXO1 protein expression - either alone or in combination with other markers - might be useful for prediction of clinical outcome in patients with EAC.
KW - Journal Article
U2 - 10.1038/s41598-018-35459-4
DO - 10.1038/s41598-018-35459-4
M3 - SCORING: Journal article
C2 - 30478420
VL - 8
SP - 17370
JO - SCI REP-UK
JF - SCI REP-UK
SN - 2045-2322
IS - 1
ER -